QuickSwitch™ Quant HLA-A*24:02 Tetramer Kit-PE

Specifications:
Background
Contact us with any specific questions you may have!
Description
QuickSwitch™ Tetramer Kit utilizes a patented technique for exchanging up to ten peptides on an MHC class I tetramer. Reduce time and cost with this kit to create your own custom tetramers. The resulting custom tetramers can be used for multiple applications, including screening immunogenic peptides.
Target: | Custom |
---|---|
Product Type: | Tetramer |
Size: | 1 kit |
Application: | FCM |
Research Area / Disease: | Immune Monitoring, Immunology |
Class: | Class I |
Allele: | HLA-A*24:02 |
Peptide Sequence: | Custom |
Conjugate: | PE |
Species Reactivity: | Human |
Specificity: | Custom |
Regulatory Statement: | For Research Use Only. Not for use in diagnostic procedures. |
Citations
Ogura, H., Gohda, J., Lu, X. et al. Dysfunctional Sars-CoV-2-M protein-specific cytotoxic T lymphocytes in patients recovering from severe COVID-19. Nat Commun 13, 7063 (2022). https://doi.org/10.1038/s41467-022-34655-1
Motozono, C., Toyoda, M., Tan, T.S. et al. The SARS-CoV-2 Omicron BA.1 spike G446S mutation potentiates antiviral T-cell recognition. Nat Commun 13, 5440 (2022). https:// doi.org/10.1038/s41467-022-33068-4
Dong et al., Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma, Cancer Cell (2021), https://doi.org/10.1016/j.ccell.2021.12.006
Morisaki T, Morisaki T, Kubo M, Onishi H, Hirano T, Morisaki S, Eto M, Monji K, Takeuchi A, Nakagawa S, Tanaka H, Koya N, Umebayashi M, Tsujimura K, Yew PY, Yoshimura S, Kiyotani K, Nakamura Y. Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis. Anticancer Res. 2021 Aug. Available at https://ar.iiarjournals.org/content/41/8/4101.abstract#sec1ps://ar.iiarjournals.org/content/41/8/4101.abstract#sec-
Poluektov, Y., Daftarian, P., & Delcommenne, M. C. (2020). Assessment of SARS-CoV-2 Specific CD4( ) and CD8 ( ) T Cell Responses Using MHC Class I and II Tetramers. Biorxiv. doi:10.1101/2020.07.08.194209